[go: up one dir, main page]

NO975977L - Substituerte purinderivater, fremgangsmÕter for fremstilling og anvendelse derav - Google Patents

Substituerte purinderivater, fremgangsmÕter for fremstilling og anvendelse derav

Info

Publication number
NO975977L
NO975977L NO975977A NO975977A NO975977L NO 975977 L NO975977 L NO 975977L NO 975977 A NO975977 A NO 975977A NO 975977 A NO975977 A NO 975977A NO 975977 L NO975977 L NO 975977L
Authority
NO
Norway
Prior art keywords
processes
preparation
purine derivatives
substituted purine
substituted
Prior art date
Application number
NO975977A
Other languages
English (en)
Other versions
NO314583B1 (no
NO975977D0 (no
Inventor
Anuschirwan Peyman
Jochen Knolle
Volkmar Wehner
Gerhard Breipohl
Jean-Fran Ois Gourvest
Denis Carniato
Thomas Richard Gadek
Original Assignee
Hoechst Ag
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag, Genentech Inc filed Critical Hoechst Ag
Publication of NO975977D0 publication Critical patent/NO975977D0/no
Publication of NO975977L publication Critical patent/NO975977L/no
Publication of NO314583B1 publication Critical patent/NO314583B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19975977A 1996-12-20 1997-12-19 Substituerte purinderivater, fremgangsmåter for fremstilling og farmasöytiske preparater inneholdende disse NO314583B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19653646A DE19653646A1 (de) 1996-12-20 1996-12-20 Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung

Publications (3)

Publication Number Publication Date
NO975977D0 NO975977D0 (no) 1997-12-19
NO975977L true NO975977L (no) 1998-06-22
NO314583B1 NO314583B1 (no) 2003-04-14

Family

ID=7815761

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19975977A NO314583B1 (no) 1996-12-20 1997-12-19 Substituerte purinderivater, fremgangsmåter for fremstilling og farmasöytiske preparater inneholdende disse

Country Status (21)

Country Link
EP (1) EP0853084B1 (no)
JP (1) JP4620190B2 (no)
KR (1) KR19980064655A (no)
CN (2) CN1495184A (no)
AR (1) AR010700A1 (no)
AT (1) ATE404562T1 (no)
AU (1) AU728865B2 (no)
BR (1) BR9706387A (no)
CA (1) CA2225366C (no)
CZ (1) CZ294437B6 (no)
DE (2) DE19653646A1 (no)
HU (1) HUP9702507A3 (no)
ID (1) ID19254A (no)
IL (1) IL122642A0 (no)
NO (1) NO314583B1 (no)
NZ (1) NZ329431A (no)
PL (1) PL323969A1 (no)
RU (1) RU2228335C2 (no)
TR (1) TR199701647A2 (no)
TW (1) TW523515B (no)
ZA (1) ZA9711317B (no)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4064059B2 (ja) 1998-04-09 2008-03-19 明治製菓株式会社 インテグリンαＶβ３拮抗剤としてのアミノピペリジン誘導体
IL143901A0 (en) 1998-12-23 2002-04-21 Searle & Co Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
EP1065208A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
US6750219B1 (en) 1999-08-05 2004-06-15 Meiji Seika Kaisha, Ltd. Ω-amino-α-hydroxycarboxylic acid derivatives having integrin ανβ3 antagonistic activity
EP1176145A1 (en) * 2000-07-28 2002-01-30 Aventis Pharma Deutschland GmbH Novel guanidino derivatives as inhibitors of cell adhesion
DE10042655A1 (de) * 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
KR100438820B1 (ko) * 2001-03-05 2004-07-05 삼성코닝 주식회사 Ιιι-ⅴ족 화합물 반도체 기판의 제조 방법
EP2292251A1 (en) 2001-04-24 2011-03-09 Merck Patent GmbH Combination therapy using anti-angiogenic agents and TNF-alpha
FR2847254B1 (fr) * 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
KR20080089489A (ko) 2006-01-18 2008-10-06 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법
ES2472450T3 (es) 2007-01-18 2014-07-01 Merck Patent Gmbh Ligandos de integrinas para su uso en el tratamiento del cáncer de colon
RU2475499C2 (ru) 2007-10-11 2013-02-20 Дайити Санкио Компани, Лимитед Антитело, направленное на белок siglec-15, связанный с остеокластами
NZ586129A (en) * 2007-11-14 2012-06-29 Myrexis Inc Therapeutic compounds and their use in treating diseases and disorders
BRPI1006134A2 (pt) 2009-04-09 2016-02-23 Daiichi Sankyo Co Ltd anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
TW201219568A (en) 2010-10-05 2012-05-16 Daiichi Sankyo Co Ltd Antibody targeting osteoclast-related protein Siglec-15
NZ631509A (en) 2012-03-30 2016-09-30 Daiichi Sankyo Co Ltd Cdr-modified anti-siglec-15 antibody
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
AR131380A1 (es) 2022-12-16 2025-03-12 Astrazeneca Ab Purinas 2,6,9-trisustituidas

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4730696Y1 (no) * 1966-12-10 1972-09-13
SU896875A1 (ru) * 1979-11-27 1995-01-09 Ленинградский химико-фармацевтический институт Способ получения 8-бромаденина
JPS6396663A (ja) * 1986-10-13 1988-04-27 Mita Ind Co Ltd 静電荷像現像用トナ−
JPS6396553A (ja) * 1986-10-14 1988-04-27 Sekisui Chem Co Ltd 充填剤
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
MX9207334A (es) * 1991-12-18 1993-08-01 Glaxo Inc Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
FR2700337B1 (fr) * 1993-01-11 1995-04-14 Lafon Labor Dérivés d'imidazopyridine-2-one, leur procédé de préparation et leur utilisation en thérapeutique.
WO1998003542A1 (en) * 1996-07-24 1998-01-29 Buchardt, Dorte Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
DE4405378A1 (de) * 1994-02-19 1995-08-24 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5554746A (en) * 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
AU702661B2 (en) * 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
WO1996020212A2 (en) * 1994-12-28 1996-07-04 Buchardt, Dorte Peptide nucleic acid incorporating a chiral backbone
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
WO1996040709A1 (en) * 1995-06-07 1996-12-19 Perseptive Biosystems, Inc. Pna-dna chimeras and pna synthons for their preparation
WO1997035846A1 (en) * 1996-03-26 1997-10-02 Dupont Pharmaceuticals Company Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
JPH1025294A (ja) * 1996-03-26 1998-01-27 Akira Matsuda 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2

Also Published As

Publication number Publication date
NZ329431A (en) 2000-01-28
PL323969A1 (en) 1998-06-22
JPH10182645A (ja) 1998-07-07
ATE404562T1 (de) 2008-08-15
CZ411497A3 (cs) 1998-07-15
HUP9702507A2 (hu) 1999-05-28
MX9710277A (es) 1998-10-31
TW523515B (en) 2003-03-11
RU2228335C2 (ru) 2004-05-10
CN1495184A (zh) 2004-05-12
HK1012190A1 (en) 1999-07-30
HUP9702507A3 (en) 1999-12-28
DE59712958D1 (de) 2008-09-25
AU728865B2 (en) 2001-01-18
EP0853084B1 (de) 2008-08-13
CN1101816C (zh) 2003-02-19
CZ294437B6 (cs) 2005-01-12
CN1193623A (zh) 1998-09-23
KR19980064655A (ko) 1998-10-07
DE19653646A1 (de) 1998-06-25
CA2225366A1 (en) 1998-06-20
EP0853084A2 (de) 1998-07-15
HU9702507D0 (en) 1998-03-02
TR199701647A3 (tr) 1998-07-21
AR010700A1 (es) 2000-06-28
EP0853084A3 (de) 1998-09-09
IL122642A0 (en) 1998-08-16
NO314583B1 (no) 2003-04-14
CA2225366C (en) 2006-10-10
JP4620190B2 (ja) 2011-01-26
BR9706387A (pt) 2000-03-14
TR199701647A2 (xx) 1998-07-21
ZA9711317B (en) 1998-06-22
AU4846697A (en) 1998-06-25
NO975977D0 (no) 1997-12-19
ID19254A (id) 1998-06-28

Similar Documents

Publication Publication Date Title
NO975977D0 (no) Substituerte purinderivater, fremgangsmåter for fremstilling og anvendelse derav
NO963015L (no) Tetracykliske derivater, fremgangsmåte for fremstilling og anvendelse
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
NO980720D0 (no) Pyridazin-3-on-derivater, deres anvendelse og mellomprodukter for deres fremstilling
IS1995B (is) Tríazól afleiður, gagnlegar í meðhöndlun
EE04721B1 (et) Fenüülksantiini derivaadid, nende valmistamismeetodid ja kasutamine
FI955235L (fi) Oksatsolidiinionijohdannaiset, niiden valmistus ja käyttö
DE69735712D1 (de) Aryl-pyrimidin-derivate
CY2013003I1 (el) Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
ATE261942T1 (de) 6-phenylpyridinderivate
IS5353A (is) Asýl-píperasínil-pýrimídínafleiður, framleiðsla og notkun þeirra sem lyfja
DK0871656T3 (da) Dolastatinderivater, deres fremstilling og anvendelse
DK1015444T3 (da) Pyrimidinderivater og fremgangsmåder til fremstilling deraf
DK0915845T3 (da) Acryloylsubstituerede distamycinderivater, fremgangsmåde til fremstilling deraf og anvendelse som antitumormidler og antivirale midler
DK0922050T3 (da) 3-Descladinose-2,3-anhydroerythromycin-derivater
NO985307L (no) Distamycinderivater, fremgangsmÕte for deres fremstilling, og deres anvende
DK0675133T3 (da) 13-Substituerede milbemycinderivater, fremstilling deraf og anvendelse deraf
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
DE69524611D1 (de) Pyrimidon-derivate
EE9800333A (et) Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
DE69724941D1 (de) Aminopyridin-derivate
NO20003268D0 (no) Hyperhydrert kitikolin, fremgangsmÕte og anvendelse
NO984921D0 (no) Tienopyridinderivater og deres anvendelse
SI0863139T1 (en) Benzoxazindione derivatives, process for their preparation and their use
DK0799238T3 (da) 14alfa, 17alfa-C2-forbundne 19-nor-progesteronderivater